| Discovery cohort (UHD) | Training cohort (UHH) | Validation cohort (UHD + UHE) | |
---|---|---|---|---|
Long-term survivors | Short-term survivors | |||
Total number, n | 39 (60.0%) | 26 (40.0%) | 91 | 83 |
Gender | ||||
 Male | 19 (48.7%) | 10 (38.5%) | 42 (46.2%) | 45 (54.2%) |
 Female | 20 (51.3%) | 16 (61.5%) | 49 (53.9%) | 38 (45.8%) |
 Unknown | 0 | 0 | 0 | 0 |
Age (years) | ||||
 Median (range) | 66.1 (40–79) | 68.3 (45–83) | 67 (33–84) | 70 (43–83) |
 Unknown | 0 | 0 | 0 | 0 |
Tumour stage | ||||
 IA | 1 (2.6%) | 1 (3.9%) | 0 | 3 (3.61%) |
 IB | 14 (35.9%) | 5 (19.2%) | 0 | 6 (7.2%) |
 IIA | 5 (12.8%) | 0 | 10 (11.0%) | 17 (20.5%) |
 IIB | 10 (25.6%) | 8 (30.8%) | 42 (46.2%) | 35 (42.2%) |
 III | 9 (23.1%) | 12 (46.2%) | 20 (22.0%) | 7 (8.4%) |
 IV | 0 | 0 | 17 (18.7%) | 15 (18.1%) |
 Unknown | 0 | 0 | 2 (2.2%) | 0 |
Cancer grade | ||||
 G1 | 2 (5.1%) | 0 | 0 | 0 |
 G2 | 20 (51.3%) | 11 (42.3%) | 45 (49.5%) | 32 (38.6%) |
 G3 | 16 (41.0%) | 15 (57.7%) | 29 (31.9%) | 39 (47.0%) |
 G4* | 0 | 0 | 1(1.1%) | 0 |
 Unknown | 1 (2.6%) | 0 | 16 (17.6%) | 12 (14.5%) |
Resection margin | ||||
 R0 | 33 (84.6%) | 18 (69.2%) | 13 (14.3%) | 64 (77.1%) |
 R1 | 6 (15.4%) | 8 (30.8%) | 65 (71.4%) | 13 (15.7%) |
 R2 | 0 | 0 | 12 (13.2%) | 1 (1.2%) |
 Unknown | 0 | 0 | 1 (1.1%) | 5 (6.0%) |
Neoadjuvant chemotherapy | ||||
 Yes | 0 | 0 | 8 (8.8%) | 13 (15.7%) |
 No | 0 | 0 | 35 (38.5%) | 51 (61.5%) |
 Unknown | 0 | 0 | 48 (52.8%) | 19 (22.9%) |
Adjuvant chemotherapy | ||||
 Yes | 29 (74.4%) | 15 (57.7%) | 42 (46.2%) | 59 (71.1%) |
 No | 9 (23.1%) | 10 (38.5%) | 10 (11.0%) | 2 (2.4%) |
 Unknown | 1 (2.6%) | 1 (3.9%) | 39 (42.9%) | 22 (26.5%) |
CA19-9 | ||||
 Median, U/ml (range) | 59.5 (0.7–3517) | 312.0 (8.5–38,878) | 182.6 (1.0–9024.4) | 189.2 (2.0–20,752.8) |
 Unknown (no. of patients) | 0 | 0 | 57 | 6 |
Follow-up time | ||||
 Median, days (range) | 2085.0 | 302.5 | 466.0 | 402.0 |
 | (1104–4575) | (194–364) | (49–3246) | (33–3803) |